To address whether the effects on the target proteins were specific to CML or apparent in other mTOR-dependent leukaemias, we tested the Jurkat leukaemia T-cell line. The gene discussed is MTOR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.